Clinical markers of post-Chikungunya chronic inflammatory joint disease: A Brazilian cohort

Imagem de Miniatura
Arquivos
art_LAZARI_Clinical_markers_of_postChikungunya_chronic_inflammatory_joint_disease_.PDF (1.01 MB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
BRESSAN, Clarisse S.
FILIPPIS, Ana Maria Bispo de
MORAES, Isabella de
CANDIDO, Darlan da Silva
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.17, n.1, article ID e0011037, 17p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundChikungunya-fever (CHIKF) remains a public health major issue. It is clinically divided into three phases: acute, post-acute and chronic. Chronic cases correspond to 25-40% individuals and, though most of them are characterized by long-lasting arthralgia alone, many of them exhibit persistent or recurrent inflammatory signs that define post-Chikungunya chronic inflammatory joint disease (pCHIKV-CIJD). We aimed to identify early clinical markers of evolution to pCHIKV-CIJD during acute and post-acute phases. Methodology/Principal findingsWe studied a prospective cohort of CHIKF-confirmed volunteers with longitudinal clinical data collection from symptoms onset up to 90 days, including a 21-day visit (D21). Of 169 patients with CHIKF, 86 (50.9%) completed the follow-up, from whom 39 met clinical criteria for pCHIKV-CIJD (45.3%). The relative risk of chronification was higher in women compared to men (RR = 1.52; 95% CI = 1.15-1.99; FDR = 0.03). None of the symptoms or signs presented at D0 behaved as an early predictor of pCHIKV-CIJD, while being symptomatic at D21 was a risk factor for chronification (RR = 1.31; 95% CI = 1.09-1.55; FDR = 0.03). Significance was also observed for joint pain (RR = 1.35; 95% CI = 1.12-1.61; FDR = 0.02), reported edema (RR = 3.61; 95% CI = 1.44-9.06; FDR = 0.03), reported hand and/or feet small joints edema (RR = 4.22; 95% CI = 1.51-11.78; FDR = 0.02), and peri-articular edema observed during physical examination (RR = 2.89; 95% CI = 1.58-5.28; FDR = 0.002). Furthermore, patients with no findings in physical examination at D21 were at lower risk of chronic evolution (RR = 0.41, 95% CI = 0.24-0.70, FDR = 0.01). Twenty-nine pCHIKV-CIJD patients had abnormal articular ultrasonography (90.6% of the examined). The most common indings were synovitis (65.5%) and joint effusion (58.6%). ConclusionThis cohort has provided important insights into the prognostic evaluation of CHIKF. Symptomatic sub-acute disease is a relevant predictor of evolution to chronic arthritis with synovitis, drawing attention to joint pain, edema, multiple articular involvement including small hand and feet joints as risk factors for chronification beyond three months, especially in women. Future studies are needed to accomplish the identification of accurate and early biomarkers of poor clinical prognosis, which would allow better understanding of the disease's evolution and improve patients' management, modifying CHIKF burden on global public health. Author summaryChikungunya fever (CHIKF) is a vector-borne viral disease first described in 1952 in Africa, which recently reached the Americas, where it then originated epidemics of unprecedented magnitude. Its acute phase is characterized by fever associated with joint pain and edema, which resolve in about seven days for most patients. However, 25-40% of these patients develop chronic musculoskeletal and arthritic symptoms, which may be incapacitating and lead to permanent joint damage. We have conducted a prospective longintudinal cohort of CHIKF confirmed individuals, in Brazil, which aimed to identify clinical early markers of evolution to post-Chikungunya chronic inflammatory joint disease (pCHIKV-CIJD) after 90 days, using objective physical examination to define pCHIKV-CIJD. We have also performed joint ultrasonography to improve evaluation of chronic arthritis. We found that 45.3% of patients who completed the follow-up met criteria for pCHIKV-CIJD. Women were at higher risk of chronification, as well as individuals who remain symptomatic 21 days after the onset of symptoms. Abnormal ultrasonography results were seen in 90.6% of examined pCHIKV-CIJD patients, in whom synovitis and joint effusion were the most commom songraphic signs, affecting mostly ankles and knees. The adoption of objective criteria to define pCHIKV-CIJD is crucial to estimate accurately the proportion of patients who evolve to chronic rheumatism, and to indentify early risk factors to this outcome, which may add important information to tailor therapeutic strategies for this particular population. It may also help to understand the burden of CHIKF in developing countries, measuring either its impact in individual's quality of life, or its communitary repercussion after widespread outbreaks.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/52975
Referências
  1. Bertolotti A, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007327
  2. Bettis A, 2022, PLOS NEGLECT TROP D, V16, DOI 10.1371/journal.pntd.0010069
  3. Brasil M da S., 2022, BRAZILIAN HLTH PORTA
  4. Brasil M da S., 2020, BRAZILIAN HLTH PORTA
  5. Brasil. M da Saude, 2017, CHIKUNGUNYA MANEJO 1
  6. Breitwieser FP, 2020, BIOINFORMATICS, V36, P1303, DOI 10.1093/bioinformatics/btz715
  7. Caglioti C, 2013, NEW MICROBIOL, V36, P211
  8. Cepeda V., 2017, BIORXIV, DOI 10.1101/212506
  9. Chang AY, 2018, ARTHRITIS RHEUMATOL, V70, P578, DOI 10.1002/art.40384
  10. Chow A, 2011, J INFECT DIS, V203, P149, DOI 10.1093/infdis/jiq042
  11. de Moraes L, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008467
  12. Edington F, 2018, JOINT BONE SPINE, V85, P669, DOI 10.1016/j.jbspin.2018.03.019
  13. Hajian-Tilaki K, 2011, CASP J INTERN MED, V2, P289
  14. Hayd RLN, 2020, CLIN RHEUMATOL, V39, P2781, DOI 10.1007/s10067-020-05011-9
  15. Heath CJ, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofx234
  16. Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
  17. Huits R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196630
  18. Kalyaanamoorthy S, 2017, NAT METHODS, V14, P587, DOI [10.1038/NMETH.4285, 10.1038/nmeth.4285]
  19. Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531
  20. Leidersnaider CL, 2022, J ULTRAS MED, V41, P865, DOI 10.1002/jum.15766
  21. Marques CDL, 2017, REV BRAS REUMATOL, V57, pS421, DOI 10.1016/j.rbre.2017.05.006
  22. Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
  23. Minh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015
  24. Mogami R, 2018, J ULTRAS MED, V37, P511, DOI 10.1002/jum.14344
  25. Morrison CR, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0017-2016
  26. Paixao ES, 2018, T ROY SOC TROP MED H, V112, P301, DOI 10.1093/trstmh/try063
  27. Pan-American Health Organization, 2022, PLISA HLTH INF PLATF
  28. Prat CM, 2014, EMERG INFECT DIS, V20, P2129, DOI 10.3201/eid2012.141269
  29. Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
  30. Ribeiro MO, 2021, BRAZ J INFECT DIS, V25, DOI 10.1016/j.bjid.2021.101542
  31. Rodrigues AM, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0583-2019
  32. Rodriguez-Morales Alfonso J, 2016, F1000Res, V5, P360, DOI 10.12688/f1000research.8235.2
  33. Rodriguez-Morales AJ, 2016, ARTHRIT CARE RES, V68, P1849, DOI 10.1002/acr.22900
  34. Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137
  35. Sepulveda-Delgado J, 2017, CLIN RHEUMATOL, V36, P695, DOI 10.1007/s10067-016-3419-2
  36. de Lima STS, 2021, CLIN INFECT DIS, V73, pE2436, DOI 10.1093/cid/ciaa1038
  37. Silva MMO, 2021, INT J INFECT DIS, V105, P608, DOI 10.1016/j.ijid.2021.03.003
  38. Simon F, 2015, MED MALADIES INFECT, V45, P243, DOI 10.1016/j.medmal.2015.05.007
  39. Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
  40. Teng TS, 2015, J INFECT DIS, V211, P1925, DOI 10.1093/infdis/jiv049
  41. van Aalst M, 2017, TRAVEL MED INFECT DI, V15, P8, DOI 10.1016/j.tmaid.2017.01.004
  42. Cavalcanti TYVD, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14050969
  43. Weaver SC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002921
  44. Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0
  45. Xavier J, 2021, INT J INFECT DIS, V105, DOI 10.1016/j.ijid.2021.01.026

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - LIM/49